Vallon Volker
Division of Nephrology-Hypertension, Departments of Medicine and Pharmacology, University of California San Diego, and VA San Diego Healthcare System, San Diego, Calif., USA.
Nephron Clin Pract. 2014;127(1-4):133-8. doi: 10.1159/000363554. Epub 2014 Sep 24.
Diabetes is the single largest contributor to the growing prevalence of chronic kidney disease (CKD), and episodes of acute kidney injury (AKI) increase the risk of advanced CKD in diabetic patients. Here we discuss whether the pathophysiological changes that occur in the tubular system of the diabetic kidney affect the intrinsic susceptibility to AKI. There is abundant data showing that drug-induced nephrotoxicity is attenuated in rodents with experimental diabetes mellitus, and some mechanistic explanations have been provided, in particular in response to aminoglycosides. Besides downregulation in proximal tubular megalin, which mediates the aminoglycoside uptake in proximal tubules, a role for hyperglycemia-induced activation of regenerative mechanisms has been proposed. The available clinical data, however, indicates that diabetes is a risk factor for AKI, including aminoglycoside nephrotoxicity. While much needs to be learned about this disconnect, the isolated induction of diabetes in otherwise healthy young adult rodents may simply not fully mimic the influence that diabetes exerts in the setting of a critically ill and often elderly patient. We speculate that diabetic tubular growth and the associated molecular signature (including upregulation of TGF-β, senescence, and inflammation) set up the development of diabetic nephropathy and renal failure in part by increasing the susceptibility to AKI, which further promotes hypoxia and apoptosis. Considering the strong association between AKI episodes and the cumulative risk of developing advanced CKD in diabetes, strategies that reduce AKI in these patients are expected to help reduce the growing burden of end-stage renal disease.
糖尿病是慢性肾脏病(CKD)患病率不断上升的最大单一因素,而急性肾损伤(AKI)发作会增加糖尿病患者发生晚期CKD的风险。在此,我们讨论糖尿病肾脏肾小管系统中发生的病理生理变化是否会影响对AKI的内在易感性。有大量数据表明,在实验性糖尿病啮齿动物中,药物诱导的肾毒性会减弱,并且已经提供了一些机制解释,特别是针对氨基糖苷类药物。除了介导近端小管中氨基糖苷类摄取的近端小管巨蛋白下调外,还提出了高血糖诱导的再生机制激活的作用。然而,现有的临床数据表明,糖尿病是AKI的一个危险因素,包括氨基糖苷类肾毒性。虽然关于这种脱节还有很多需要了解的地方,但在其他方面健康的年轻成年啮齿动物中单纯诱导糖尿病可能无法完全模拟糖尿病在重症且通常为老年患者环境中所产生的影响。我们推测,糖尿病肾小管生长及相关分子特征(包括TGF-β上调、衰老和炎症)部分通过增加对AKI的易感性来促进糖尿病肾病和肾衰竭的发展,而这又进一步促进缺氧和细胞凋亡。鉴于AKI发作与糖尿病患者发生晚期CKD的累积风险之间存在密切关联,预计降低这些患者AKI的策略将有助于减轻终末期肾病日益增加的负担。